decorative image

2021 American Society of Hematology (ASH) Annual Meeting and Exposition

December 10 - 14 , 2021
Virtual & Atlanta, GA


NHLBI will participate in the 2021 American Society of Hematology (ASH) Meeting & Exposition from December 10-14, 2021, offered both in-person in Atlanta, Georgia, and through a virtual format. NHLBI research and NHLBI-funded research will be presented at more than 50 sessions. See the schedule below for a snapshot of these sessions. Visit the ASH 2021 Annual Meeting website for a full schedule and updates.

Friday, December 10, 2021

Scientific Workshop

Streamlining Hematology Clinical Trials; Lessons Learned from a Global Pandemic
Speakers: Jean M Connors, M.D.
2:00-5:00 p.m. ET

Saturday, December 11, 2021

Special-Interest Session

What's New in the Transfusion Management of Sickle Cell Disease?
Chair: Michael Murphy, M.D.
Speakers: Venee N.Tubman, M.D., France Pirenne, M.D., Ph.D., Jeanne E. Hendrickson, M.D.
4:00 – 4:45 p.m. ET

Oral and Poster Abstracts

Session 701

Carbapenem Antibiotics Promote Mucus Degradation By Bacteroides and Aggravate Graft-Versus-Host Disease
Eiko Hayase, M.D., Ph.D.
9:30 a.m. ET

Immune-Mediated Reprogramming of Intestinal Stem Cells Drives STAT1-Dependent Myc Expression and Epithelial Regeneration in GI-Gvhd
Shuichiro Takashima, M.D., Ph.D.
9:45 a.m. ET

Corticosteroid Treatment Impairs Epithelial Regeneration, Limiting Intestinal Recovery in Experimental Graft Vs Host Disease
Viktor Arnhold, M.D.
10:15 a.m. ET

Session 114

Hydroxyurea Reduces the Transfusion Burden in Children with Sickle Cell Anemia: The Reach Experience
Alexandra Power-Hays
9:30 – 11:00 a.m. ET

Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: New Therapies for Sickle Cell Disease
Julia Z. Xu, MD, MS, Anna Conrey, NP, and Neal Jeffries, PhD
10:15 a.m. ET

Prevalence and Factors Associated with Echocardiographic Abnormalities in Children with Sickle Cell Disease; Results from the Displace Study
Najibah Galadanci
12:00 – 1:30 p.m. ET

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT
Emily Limerick, M.D.
5:30 – 7:30 p.m. ET

Session 501

Lin28b-Let-7-PRC1 Axis Guides Developmental Maturation of the Hematopoietic System
Mayuri Tanaka-Yano, Ph.D.
10:00 a.m. ET

Session 801

Mitapivat (AG-348) Demonstrates Safety, Tolerability, and Improvements in Anemia, Hemolysis, Oxygen Affinity, and Hemoglobin S Polymerization Kinetics in Adults with Sickle Cell Disease: A Phase 1 Dose Escalation Study
Julia Z. Xu, M.D.
10:15 a.m. ET

Single Cell RNA-Seq Characterization of an Adaptive Population of NK Cells after Primary CMV Infection in Rhesus Macaques
Stefan Cordes, M.D.
2:00 p.m. ET

Session 636

Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes
Federico Gaiti, Ph.D.
12:00 p.m. ET

Session 803

Assessment of Next Generation Sequencing Approaches for the Cytogenetic and Molecular Evaluation of Acute Myeloid Leukemia
Laura W. Dillon, Ph.D.
2:00 p.m. ET

Session 331

Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant
Meaghan Colling, M.D.
4:15 p.m. ET

Session 113

Individuals with Sickle Cell Disease Have a Higher Burden of Mitochondrial DNA Heteroplasmy
Laxminath Tumburu, Ph.D.
5:30 – 7:30 p.m. ET

Pklr Is a Genetic Modifier of Sickle Cell Disease
Xunde Wang, Ph.D.
5:30 – 7:30 p.m. ET

Session 642

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine
Christopher Pleyer, M.D.
5:30 – 7:30 p.m. ET

Session 203

Tissue-Resident Clonal Expansions of Rhesus Macaque NK Cells
Chuanfeng Wu, Ph.D.
5:30 – 7:30 p.m. ET

Session 617

Highly Multiplexed Cell Surface Immunophenotyping with Genotyping and Concurrent Transcriptomic Analysis of NPM1 mutated Acute Myeloid Leukemia
Devdeep Mukherjee, Ph.D.
5:30 – 7:30 p.m. ET

Single-Cell Transcriptomic and Proteomic Analysis of Acute Myeloid Leukemia (AML) Patients with Abnormalities on Chromosome 7
Gege Gui
5:30 – 7:30 p.m. ET

Session 508

Clonal Hematopoiesis in Telomere Biology Disorders Associates with the Underlying Germline Defect and Somatic Mutations in POT1, PPM1D, and TERT promoter
Fernanda Gutierrez-Rodrigues, Ph.D.
5:30 – 7:30 p.m. ET

Session 1859

Lentiviral Vector-Mediated Gene Transfer Restores CD18 Expression in Long-Term Repopulating Hematopoietic Stem and Progenitor Cells Isolated from a Patient with Leukocyte Adhesion Deficiency Type 1
Richard Smith, Ph.D.
5:30 – 7:30 p.m. ET

Sunday, December 12, 2021

Special Interest Sessions

Curative Therapies and Considerations for Sickle Cell Disease
Julie Kanter, M.D., Lakshmanan Krisnamurti, M.D., Sherif M. Badawy, M.D.
9:30 – 10:15 a.m. ET

Special Scientific Sessions

Human Pluripotent Stem Cell-Derived Hematopoiesis: From Development to Stem Cell Therapies
Christopher M. Sturgeon, Ph.D.
4:30 – 5:15 p.m. ET

Oral and Poster Abstracts

Session 904

Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)
Staci Arnold
9:30 – 11:00 a.m. ET

Session 723

Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation
Andrew St. Martin
9:30 – 11:00 a.m. ET

Long-Term Cardiac Effects of Successful Non-Myeloablative HLA-Matched Sibling Transplants in Sickle Cell Disease
Vandana Sachdev, M.D.
6:00 – 8:00 p.m. ET

Session 801

Clonal Tracking By Whole Genome Sequencing Permits Comprehensive Mapping of the Genomic Landscape in Pre- and Post-Gene Therapy Sickle Cell Patients
Alyssa H. Cull, Ph.D.
4:30 p.m. ET

CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model
Naoya Uchida, M.D.
4:45 p.m. ET

Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)
John Tisdale, M.D.
5:00 p.m. ET

Gene Delivery Using Baculovirus in Human Hematopoietic Stem and Progenitor Cells Requires Inhibition of Cellular Innate Immune Pathways
Christi Salisbury-Ruf, Ph.D.
6:00 – 8:00 p.m. ET

Administration of Granulocyte Colony-Stimulating Factor Post-Transplant Impedes Engraftment of CRISPR-Cas9 Edited Long-Term Repopulating Hematopoietic Stem and Progenitor Cells
Daisuke Araki, M.D.
6:00 – 8:00 p.m. ET

Session 508

Prospective Phase I/II Study of Eltrombopag for the Treatment of Bone Marrow Failure in Fanconi Anemia
Andre Larochelle, M.D., Ph.D.
6:00 – 8:00 p.m. ET

Rhesus Macaques As a Preclinical Model Organism for RUNX1-FPD
Byung-Chul Lee, Ph.D.
6:00 – 8:00 p.m. ET

Genomic-Based Machine Learning Towards Prediction of the Etiology of Bone Marrow Failure Syndromes
Fernanda Gutierrez-Rodrigues, Ph.D.
6:00 – 8:00 p.m. ET

Granulocytic Myeloid-Derived Suppressor Cells in Murine Models of Immune-Mediated Bone Marrow Failure
Xingmin Feng, Ph.D.
6:00 – 8:00 p.m. ET

Session 113

Effects of Quercetin on Neutrophil Extracellular Trap Formation in Sickle Cell Disease
Bindu Parachalil Gopalan, Ph.D.
6:00 – 8:00 p.m. ET

Effects of Flavonoid Quercetin on Thrombo-Inflammatory Processes in Patients with Sickle Cell Disease
Maria A. Lizarralde, Ph.D.
6:00 – 8:00 p.m. ET

Session 605

Treatment with BTK Inhibitor or Bcl-2 Inhibitor Increases Cytotoxicity of the Anti-CD3xCD20 Bispecific Antibody Epcoritamab Against Chronic Lymphocytic Leukemia
Maissa Mhibik, Ph.D.
6:00 – 8:00 p.m. ET

Session 701

Diphtheria Toxin Based Bivalent Anti-cMPL Immunotoxin Effectively Depletes Human Hematopoietic Stem and Progenitor Cells
Daisuke Araki, M.D.
6:00 – 8:00 p.m. ET

Monday, December 13, 2021

Special Interest Sessions

Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease
Ted Wun, M.D., John J. Strouse, M.D., Ph.D., Ifeyinwa (IFY) Osunkwo, M.D., Ph.D.
10:30 a.m. – 12:00 p.m. ET

Management Strategies for Sickle Cell Disease
Chair: Nirmish Shah, M.D.
Speakers: Leila Jerome Clay, M.D., Charity I. Oyedeji, M.D., Payal Desai, M.D.
2:45 – 3:30 p.m. ET

Epidemiology and Clinical Risk Factors for AML Outcome in Older Adults
Christopher S. Hourigan, D.M., D.Phil
4:30 – 6:00 p.m. ET

Special Scientific Sessions

Of Lineage and Legacy: Applications of Lineage Tracing in Hematology
Vijay G. Sankaran, M.D., Ph.D.
2:45 – 3:30 p.m. ET

Oral and Poster Abstracts

Session 508

Strong Predictors of Chromosomal Aberrations and Myeloid Neoplasia Following Immunosuppression Therapy for Severe Aplastic Anemia: A Retrospective Cohort Study
Emma M. Groarke, M.D.
10:30 a.m. ET

U2AF1 and Other Splicing Factor Gene Mutations in Telomere Biology Disorders Are Associated with Hematologic Neoplasia and Worse Overall Survival
Emma M. Groarke, M.D.
7:00 p.m. ET

Session 721

Nutrition As a Predictor of Microbiome Injury in Allo-HCT
Anqi Dai
3:00 p.m. ET

Session 331

Silent Cerebral Infarction on Brain MRI Is Associated with Cognitive Impairment in Ittp Survivors in Hematological Remission
Jia Yu
5:45 p.m. ET

Inhibition of Sars-Cov-2 Viral Replication and In Vivo Thrombus Formation By a Novel Plant Flavonoid
Moua Yang, Ph.D.
6:00 p.m. ET

Session 503

Evaluation of the Relationship between Clonal Hematopoiesis and Severe COVID-19 Disease in Rhesus Macaques
Taehoon Shin, Ph.D.
6:00 – 8:00 p.m. ET

Session 642

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL
Clare Sun, M.D.
6:00 – 8:00 p.m. ET

Session 722

A New Diagnostic Classification Tool for Pulmonary Chronic Graft-Versus-Host-Disease: Adaptation of the International Society for Heart and Lung Transplantation Chronic Lung Allograft Dysfunction Consensus Criteria
Yifan Pang, M.D.
6:00 – 8:00 p.m. ET

Session 901

Grapes: Trivia Game Increases Sickle Cell Disease Knowledge in Patients and Providers and Mitigates Health Biases
Amy Ouyang
7:15 p.m. ET